34-Year-Old Man Presents With a Soft Tissue Induration in the Right Thigh

Poll

A 34-year-old man presents with a soft tissue induration in the right thigh. A biopsy of the mass is performed. What is your diagnosis?

A 34-year-old man presents with a soft tissue induration in the right thigh.  A biopsy of the mass is performed and is shown below.

What is your diagnosis?

A. Malignant melanoma
B. Peripheral T-cell lymphoma
C. Metastatic carcinoma
D. Rhabdomyosarcoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
Related Content
The trial had an estimated enrollment of 50 patients who received oral TT125-802 as a single agent.

FDA Grants 2 Fast Track Designations to TT125-802 in EGFR/KRAS G12C NSCLC

Tim Cortese
August 29th 2025
Article
Beyond the BEP: A Deep Dive into Testicular Cancer Management

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Nabil Adra, MD
August 29th 2025
Podcast
The median disease-free survival was 9.41 months in the TAS-102 cohort compared with 5.75 months in the synthetic control arm.

Though TAS-102 Achieved ctDNA Clearance, More Work is Needed

Tim Cortese
August 29th 2025
Article
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 29th 2025
Podcast
Results came from the pilot, open-label, phase 2 QUILT-3.078 trial (NCT06061809) that evaluated nogapendekin alfa inbakicept with PD-L1 t-haNK and bevacizumab in patients with recurrent or progressive glioblastoma.

Nogapendekin Alfa Inbakicept Combo Yields Disease Control in Glioblastoma

Tim Cortese
August 29th 2025
Article
Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Ariana Pelosci
August 29th 2025
Article